Retinoids synergize with interleukin-2 to augment IFN-γ and interleukin-12 production by human peripheral blood mononuclear cells

Journal of Interferon and Cytokine Research

Volumn 19, Issue 4, 1999, Pages 407-415

  Fox, Floyd E ^a   Kubin, Marek ^b   Cassin, Maureen ^a   Niu, Zhutian ^a   Trinchieri, Giorgio ^b   Cooper, Kevin D ^c   Rook, Alain H ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ETRETINATE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; RETINOIC ACID; RETINOID;

ARTICLE; CELL DIFFERENTIATION; CELL POPULATION; DRUG EFFECT; DRUG POTENTIATION; GROWTH INHIBITION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; MOLECULAR CLONING; MONONUCLEAR CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN FAMILY; RADIOIMMUNOASSAY;

ANTIGEN-ANTIBODY REACTIONS; DRUG SYNERGISM; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; RETINOIDS; SEZARY SYNDROME; TH1 CELLS;

ATRA;

EID: 0032897317     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099314117     Document Type: Article

References (29)

1. BLOMHOFF, R., GREEN, M.H., BERG, T., and NORUM, K.R. (1990). Transport and storage of vitamin A. Science 250, 399-404.
2. McCOLLUM, E.V., and DAVID, M. (1913). The necessity of certain lipids in the diet during growth. J. Biol. Chem. 15, 167.
3. WARD, A., BROGDEN, R.N., HEEL, R.C., SPEIGHT, T.M., and AVERY, G.S. (1983). Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders. Drugs 26, 9-43.
4. EHMANN, C.W., and VOORHEES, J.J. (1982). International studies of the efficacy of etretinate in the treatment of psoriasis. J. Am. Acad. Dermatol. 6, 692-696.
5. MAHRLE, G., MEYER-HAMME, S., and IPPEN, H. (1982). Oral treatment of keratinizing disorders of skin and mucous membranes with etretinate. Comparative study of 113 patients. Arch. Dermatol. 118, 97-100.
6. EPSTEIN, J.H. (1986). All-trans-retinoic acid and cutaneous cancers. J. Am. Acad. Dermatol. 15, 772-778.
7. LIPPMAN, S.M., and MEYSKENS, E.L.J. (1987). Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann, Intern. Med. 107, 499-502.
8. SMITH, M.A., PARKINSON, D.R., CHESON, B.D., and FRIEDMAN, M.A. (1992). Retinoids in cancer therapy. J. Clin. Oncol. 10, 839-864.
9. KESSLER, J.F., JONES, S.E., LEVINE, N., LYNCH, P.J., BOOTH, A.R., and MEYSKENS, F.L.J. (1987). Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch. Dermatol. 123, 201-204.
10. KESSLER, J.F., MEYSKENS, F.L.J., LEVINE, N., LYNCH, P.J., and JONES, S.E. (1983). Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet 1, 1345-1347.
11. VOWELS, B.R., CASSIN, M., VONDERHEID, E.C., and ROOK, A.H. (1992). Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J. Invest. Dermatol. 99, 90-94.
12. VOWELS, B.R., LESSIN, S.R., CASSIN, M., JAWORSKY, C., BENOIT, B., WOLFE, J.T., and ROOK, A.H. (1994). Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J. Invest. Dermatol. 103, 669-673.
13. ROOK, A.H., KUBIN, M., CASSIN, M., VONDERHEID, E.C., VOWELS, B.R., WOLFE, J.T., WOLFE, S.E., SINGH, A., TRINCHIERI, G., and LESSIN, S.R. (1995). IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J. Immunol. 154, 1491-1498.
14. TRINCHIERI, G. (1995). Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13, 251-276.
15. STINGL, G., TAMAKI, K., and KATZ, S.I. (1980). Origin and function of epidermal Langerhans cells. Immunol. Rev. 53, 149-174.
16. CHEN, G., KANG, K., KANG, S., ROOK, A.H., KUBIN, M., VOORHEES, J.J., and COOPER, K.D. (1996). Differential induction of IL-12 p40 and IL-10 mRNA in human Langerhans cells and keratinocytes by in vivo occlusion, vehicle and all-trans retinoic acid. J. Cutan. Med. Surg. 1, 74-80.
17. MEUNIER, L., BOHJANEN, K., VOORHEES, J.J., and COOPER, K.D. (1994). Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, a beta 2 integrin critically involved in T-cell activation. J. Invest. Dermatol. 103, 775-779.
18. DENNERT, G., and LOTAN, R. (1978). Effects of retinoic acid on the immune system: stimulation of T killer cell induction. Eur. J. Immunol. 8, 23-29.
19. GOLDFARB, R.H., and HERBERMAN, R.B. (1981). Natural killer cell reactivity: regulatory interactions and among phorbol ester, interferon, cholera toxin, and retinoic acid. J. Immunol. 126, 2129-2135.
20. DUMMER, R., KOHL, O., GILLESSEN, J., KAGI, M., and BURG, G. (1993). Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. Arch. Dermatol. 129, 433-436.
21. HOPPE, R.T., MEDEIROS, L.J., WARNKE, R.A., and WOOD, G.S. (1995). CDS-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J. Am. Acad. Dermatol. 32, 448-453.
22. BERGER, C, LIU, W., HEALD, P., CHRISTENSEN, I., and EDELSON, R, (1994). Antitumor response in cutaneous T-cell lymphoma. J. Invest. Dermatol. 102, 566. (abstract)
23. DRENO, B. (1993). Roferon-A (interferon alpha 2a) combined with Tigison (etretinate) for treatment of cutaneous T cell lymphornas. Stem Cells 11, 269-275.
24. GOTTLIEB, S.L., HAYES, E., GILLEAUDEAU, P., CARDINALE, I., GOTTLIEB, A.B., and KRUEGER, J.G. (1996). Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. J. Cutan. Pathol. 23, 404-418.
25. SIDELL, N., CHANG, B., and BHATTI, L. (1993). Upregulation by retinoic acid of interleukin-2-receptor mRNA in human T lymphocytes. Cell. Immunol. 146, 28-37.
26. HANG, X.L., EVERSON, M.P., and LAMON, E.W. (1993). A mechanism of retinoid potentiation of murine T-cell responses: early Upregulation of interleukin-2 receptors. Int. J. Immunopharmacol. 15, 309-317.
27. DUVIC, M., LEMAK, N.A., REDMAN, J.R., EIFEL, P.J., TUCKER, S.L., CABANILLAS, F.F., and KURZROCK, R. (1996). Combined modality therapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 34, 1022-1029.
28. OLSEN, E.A., and BUNN, P.A. (1995). Interferon in the treatment of cutaneous T-cell lymphoma. Hematol. Oncol. Clin. North Am. 9, 1089-1107.
29. TORII, H., KANEKO, T., MATSUYAMA, T., NAKANISHI, H., and HARADA, S. (1994). Interferon-alpha (IFN-alpha) and etretinate in the treatment of mycosis fungoides. J. Dermatol. 21, 767-770.